Tetrahydromagnolol

CAS No. 20601-85-8

Tetrahydromagnolol( —— )

Catalog No. M21696 CAS No. 20601-85-8

Tetrahydromagnolol can activate cannabinoid (CB) receptors.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 58 In Stock
5MG 48 In Stock
10MG 74 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Tetrahydromagnolol
  • Note
    Research use only, not for human use.
  • Brief Description
    Tetrahydromagnolol can activate cannabinoid (CB) receptors.
  • Description
    Tetrahydromagnolol can activate cannabinoid (CB) receptors.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Cannabinoid Receptor
  • Recptor
    Cannabinoid Receptor|GPR|GABA
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    20601-85-8
  • Formula Weight
    270.4
  • Molecular Formula
    C18H22O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (369.86 mM)
  • SMILES
    CCCc(cc1)cc(-c(cc(CCC)cc2)c2O)c1O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Repertaxin

    Reparixin is a potent inhibitor of both CXCL8 receptors?CXCR1/2, it inhibits weakly?CXCR2-mediated cell migration (IC50=100 nM), whereas it strongly blocks?CXCR1-mediated chemotaxis (IC50=1 nM).

  • CB1 inverse agonist ...

    CB1 inverse agonist 1 (MRL-650) is an orally active and selective CB1 agonist. The IC50s for CB1 and CB2 are 7.5 nM and 4100 nM, respectively.

  • Tetrahydrocannabivar...

    Tetrahydrocannabivarin is a neutral cannabis receptor subtype (CB1) receptor antagonist, it can increases neural responding to rewarding and aversive stimuli, this effect profile suggests therapeutic activity in obesity, perhaps with a lowered risk of depressive side effects. Tetrahydrocannabivarin exhibits anticonvulsant effects in a piriform cortical brain slice model of epileptiform activity.